<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201211</url>
  </required_header>
  <id_info>
    <org_study_id>204913</org_study_id>
    <secondary_id>2016-004248-13</secondary_id>
    <nct_id>NCT03201211</nct_id>
  </id_info>
  <brief_title>A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults</brief_title>
  <official_title>A Long-term Follow-up Study of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this long-term follow-up of a Phase I study is to evaluate the kinetics of the
      antibody response to NTHi-Mcat antigens and long-term safety, in subjects aged between 50-71
      years at the time of enrolment in the NTHi-Mcat-001 study. These subjects were previously
      exposed to two adjuvanted formulations of the NTHi-Mcat vaccine administered according to a
      0, 2 months schedule in the NTHi-Mcat-001 (201281) study. The subjects that had received
      saline placebo controls will also be included in this follow-up study to make comparisons
      with the investigational vaccines. No vaccinations will be administered in this trial.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">March 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Protein D (PD) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 20</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations),. The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PD assay is 153 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein D (PD) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 26</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations),. The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PD assay is 153 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein D (PD) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 32</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PD assay is 153 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein D (PD) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 38</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PD assay is 153 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein D (PD) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 44</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PD assay is 153 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein D (PD) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 50</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PD assay is 153 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein E (PE) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 20</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PE assay is 8 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein E (PE) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 26</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PE assay is 8 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein E (PE) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 32</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PE assay is 8 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein E (PE) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 38</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations).The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PE assay is 8 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein E (PE) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 44</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PE assay is 8 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Protein E (PE) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 50</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PE assay is 8 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-type IV pili subunit (PilA) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 20</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PilA assay is 7 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-type IV pili subunit (PilA) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 26</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PilA assay is 7 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-type IV pili subunit (PilA) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 32</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PilA assay is 7 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-type IV pili subunit (PilA) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 38</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PilA assay is 7 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-type IV pili subunit (PilA) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 44</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PilA assay is 7 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-type IV pili subunit (PilA) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 50</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-PilA assay is 7 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 20</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-UspA2 assay is 18 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 26</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-UspA2 assay is 18 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 32</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-UspA2 assay is 18 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 38</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-UspA2 assay is 18 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 44</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations). The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-UspA2 assay is 18 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations, measured as component of the NTHi Mcat investigational vaccine.</measure>
    <time_frame>At Month 50</time_frame>
    <description>Geometric Mean Concentrations (GMC) and their 95% CI will be calculated (the GMCs are computed by taking the anti-log of the mean of the log concentration transformations) The cut-off value of the enzyme-linked immunosorbent assay (ELISA) anti-UspA2 assay is 18 EU/mL (ELISA unit per millilitre).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reported with any serious adverse event (SAE).</measure>
    <time_frame>From first visit (Month 20) up to study conclusion (Month 50)</time_frame>
    <description>A Serious Adverse Event is any untoward medical occurrence that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reported with any potential immune-mediated disease (pIMD).</measure>
    <time_frame>From first visit (Month 20) up to study conclusion (Month 50)</time_frame>
    <description>Potential immune-mediated diseases (pIMDs) are a subset of Adverse Events that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Respiratory Disorders</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received two doses of formulation 1 of the NTHi-Mcat investigational vaccine during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received two doses of formulation 2 of the NTHi-Mcat investigational vaccine during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who received placebo during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Formulation 1 : NTHi-Mcat high dose adjuvanted vaccine GSK3277513A</intervention_name>
    <description>2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Formulation 2 : NTHi-Mcat low dose adjuvanted vaccine GSK3339036A</intervention_name>
    <description>2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who previously participated in STEP 2 of study NTHi-Mcat-001 (201281), and
             performed the last study visit (Month 14) and received the 2 study vaccinations.

          -  Subjects who, in the opinion of the investigator, can and will comply with the
             requirements of the protocol (e.g. return for follow-up visits). And subjects' Legally
             Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and
             will comply, with the requirements of the protocol.

          -  Written informed consent obtained from the subject/ LAR(s) of the subject prior to
             performance of any study specific procedure.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) during the
             period starting 30 days before the first follow-up study visit (Month 19 to Month 20),
             or planned use during the study period.

          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants
             or other immune-modifying drugs since the end of the NTHi-Mcat-001 study. For
             corticosteroids, this will mean prednisone â‰¥ 20 mg/day, or equivalent. Inhaled and
             topical steroids are allowed.

          -  Administration of long-acting immune-modifying drugs at any time during the study
             period (e.g. infliximab).

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational vaccine/product (pharmaceutical product or device).

          -  Administration of immunoglobulins and/or any blood products during the period starting
             3 months before the first follow-up visit or planned administration during the study
             period.

          -  Current alcoholism and/or drug abuse.

          -  Has significant disease (including significant neurological or psychological
             disorders), in the opinion of the investigator, likely to interfere with the study
             and/or likely to cause death within the study duration.

          -  Any other condition that the investigator judges may interfere with study findings.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

